Hal Gunn, MD, founder and CEO of Qu Biologics, is a physician-entrepreneur who has dedicated his professional life to understanding how to optimally support the body’s innate immune capacity to heal. Dr. Gunn is recognized both nationally and internationally as a leader in the field of supportive oncology and was awarded the $250,000 Dr. Roger’s Prize for Advancing Health, Medicine, and Healing for vision, leadership, and integrity in the field of Integrative Medicine.

Dr. Gunn co-founded InspireHealth, Canada’s foremost supportive cancer care centre, to support the health, healing, and immune system function of people undergoing cancer treatment and their families. Under Dr. Gunn’s leadership, InspireHealth grew to become a world leader in supportive cancer care with three centres, funded by the Provincial government.

Dr. Gunn founded Qu Biologics to develop his discovery of the Site Specific Immunomodulation (SSI) platform designed to restore the full depth and breadth of immune function in a targeted organ.

Dr. Gunn obtained his Doctorate of Medicine from the University of British Columbia (UBC) and remains a Clinical Assistant Professor at UBC’s School of Medicine.

Dr. Gunn is the inventor of >80 granted patents in the fields of biotechnology and technology.

Dr. Gunn discovered the Site Specific Immunomodulation platform and has led Qu, as CEO and Board Chair, since Qu’s founding, including building Qu’s Board and leadership team and leading Qu’s clinical development strategy. Dr. Gunn serves on Qu’s Governance and Nomination Committee and Qu’ Compensation Committee.